Clinical Policy: Corticotropin (H.P. Acthar) Reference Number: ERX.SPA.72 Effective Date:
|
|
- Melvyn Henry
- 5 years ago
- Views:
Transcription
1 Clinical Plicy: (H.P. Acthar) Reference Number: ERX.SPA.72 Effective Date: Last Review Date: Revisin Lg See Imprtant Reminder at the end f this plicy fr imprtant regulatry and legal infrmatin. Descriptin (H.P. Acthar ) is an adrencrtictrpic hrmne analgue. FDA Apprved Indicatin(s) H.P. Acthar is indicated: Fr the treatment f infantile spasms in infants and children under 2 years f age as mntherapy Fr the treatment f exacerbatins f multiple sclersis (MS) in adults H.P. Acthar Gel may als be used fr the fllwing disrders and diseases: rheumatic, cllagen, dermatlgic, allergic states, phthalmic, respiratry, and edematus state. Plicy/Criteria Prvider must submit dcumentatin (which may include ffice chart ntes and lab results) supprting that member has met all apprval criteria. It is the plicy f health plans affiliated with Envlve Pharmacy Slutins that H.P. Acthar is medically necessary when the fllwing criteria are met: I. Initial Apprval Criteria A. West Syndrme (Infantile Spasms) (must meet all): 1. Diagnsis f West syndrme (infantile spasms); 2. Prescribed by r in cnsultatin with a neurlgist; 3. Age < 2 years; 4. Dse des nt exceed 150 U/m 2 per day (divided int twice daily IM injectins f 75 U/m 2 ). Apprval duratin: 3 mnths B. Multiple Sclersis (must meet all): 1. Diagnsis f MS; 2. Prescribed by r in cnsultatin with a neurlgist; 3. Age 18 years; 4. Prescribed fr acute exacerbatins f MS; 5. Failure f a recent (within the last 30 days) trial f at least 7 day curse f crticsterid therapy fr acute exacerbatins f MS, unless cntraindicated r clinically significant adverse effects are experienced; 6. Dse des nt exceed 120 units per day. Apprval duratin: 1 mnths C. Nephrtic Syndrme (must meet all): a. Diagnsis f nephrtic syndrme and assciated (a r b): a. Systemic lupus erythematsus; b. Idipathic nephrpathy/glmerulnephritis; b. Prescribed by r in cnsultatin with a nephrlgist; c. Age > 2 years; d. Failure f ral sterids, unless cntraindicated r clinically significant adverse effects are experienced; e. Failure f 2 f the fllwing agents: tacrlimus, cyclsprine, mycphenlate, rituximab, unless cntraindicated r clinically significant adverse effects are experienced; f. Dse des nt exceed 80 units given intramuscularly r subcutaneusly every 24 hurs. Page 1 f 5
2 Apprval duratin: 3 mnths B. Other diagnses/indicatins 1. Refer t ERX.PA.01 if diagnsis is NOT specifically listed under sectin III (Diagnses/Indicatins fr which cverage is NOT authrized). II. Cntinued Therapy A. West Syndrme (Infantile Spasms) (must meet all): 1. Currently receiving medicatin via a health plan affiliated with Envlve Pharmacy Slutins r member has previusly met initial apprval criteria; 2. Age is < 2 years ld; 3. Member is respnding psitively t therapy; 4. If request is fr a dse increase, new dse des nt exceed 150 U/m 2 per day (divided int twice daily injectins f 75 U/m 2 ). Apprval duratin: 3 mnths (West syndrme ne renewal limit) B. Multiple Sclersis: HP Acthar is nt indicated fr cntinuus use fr this indicatin. Reauthrizatin requests must be reviewed against the initial apprval criteria. C. Nephrtic Syndrme (must meet all): 1. Currently receiving medicatin via a health plan affiliated with Envlve Pharmacy Slutins r member has previusly met initial apprval criteria; 2. Prescribed by r in cnsultatin with a nephrlgist; 3. Dcumentatin f psitive respnse t therapy; 4. Dse des nt exceed 80 units given intramuscularly r subcutaneusly every 24 hurs. Apprval duratin: 3 mnths D. Other diagnses/indicatins (must meet 1 r 2): 1. Currently receiving medicatin via a health plan affiliated with Envlve Pharmacy Slutins and dcumentatin supprts psitive respnse t therapy. Apprval duratin: Duratin f request r 3 mnths (whichever is less); r 2. Refer t ERX.PA.01 if diagnsis is NOT specifically listed under sectin III (Diagnses/Indicatins fr which cverage is NOT authrized). III. Diagnses/Indicatins fr which cverage is NOT authrized: A. Nn-FDA apprved indicatins, which are nt addressed in this plicy, unless there is sufficient dcumentatin f efficacy and safety accrding t the ff-label use plicy ERX.PA.01 r evidence f cverage dcuments. IV. Appendices/General Infrmatin Appendix A: Abbreviatin/Acrnym Key ACTH: adrencrtictrpic hrmne MS: multiple sclersis Appendix B: Therapeutic Alternatives Nt applicable. Appendix C: General Infrmatin Cmmn adverse reactins fr H.P. Acthar Gel are similar t thse f crticsterids and include fluid retentin, alteratin in glucse tlerance, elevatin in bld pressure, behaviral and md changes, increased appetite and weight gain. The initial apprval f H.P. ACTH gel ccurred prir t the Kefauver-Harris amendment t the Federal Fd, Drug and Csmetic Act f 1962, which intrduced the requirement f substantial evidence f tw adequate and well cntrlled trials. At the time f the riginal apprval drug manufacturers nly had t shw the drug was safe fr use in humans. The riginal data included Page 2 f 5
3 case reprts frm a few physicians describing patients with cnditins riginally treated with Acthar pwder that were transferred t treatment with Acthar Gel and gave dsing guidance fr treatment f these individual cnditins. The efficacy H.P. Acthar Gel in the fllwing cnditins has nt been prven in well-designed clinical trials and its use is cnsidered experimental, They are als nt FDA apprved indicatins: Rheumatic Disrders: As adjunctive therapy fr shrt-term administratin (t tide the patient ver an acute episde r exacerbatin) in: psriatic arthritis, rheumatid arthritis, including juvenile rheumatid arthritis (selected cases may require lw-dse maintenance therapy), ankylsing spndylitis Cllagen Diseases: During an exacerbatin r as maintenance therapy in selected cases f: systemic lupus erythematsus; systemic dermatmysitis (plymysitis) Dermatlgic Diseases: severe erythema multifrme, Stevens-Jhnsn syndrme Allergic States: serum sickness Ophthalmic Diseases: severe acute and chrnic allergic and inflammatry prcesses invlving the eye and its adnexa such as: keratitis, iritis, iridcyclitis, diffuse psterir uveitis and chriditis; ptic neuritis; chriretinitis; anterir segment inflammatin Respiratry Diseases: symptmatic sarcidsis Edematus State: T induce a diuresis r a remissin f prteinuria in the nephrtic syndrme withut uremia f the idipathic type r that due t lupus erythematsus Fr acute exacerbatins in multiple sclersis, the results f trials that analyzed direct cmparisns have shwn n significant differences between ACTH and methylprednislne (MP) in bth rate and degree f recvery after exacerbatin. Indirect cmparisns suggest a significantly greater effect f MP versus ACTH, with MP cnferring greater benefit cmpared with ACTH (dds rati (OR) 0.20, 95% CI 0.09 t 0.45 vs OR 0.46, 95% CI 0.28 t 0.77). Studies evaluating the use f ACTH in acute exacerbatins f multiple sclersis ranged frm 14 t 21 days in length and evaluated ne curse f therapy. T date, retreatment with ACTH has nt been evaluated in clinical trials. V. Dsage and Administratin Indicatin Dsing Regimen Maximum Dse West syndrme (infantile 150 U/m 2 IM divided int twice daily injectins f 150 U/m 2 /day spasms) 75 U/m 2 administered ver a 2-week perid. After 2 weeks, H.P. Acthar shuld be gradually tapered ver a 2-week perid Acute exacerbatin f MS units IM r SC daily fr 2-3 weeks 120 units/day Nephrtic syndrme 80 units IM r SC every 24 hurs 80 units/day VI. Prduct Availability Multi-dse vial: 5 ml cntaining 80 USP units per ml VII. References 1. H.P. Acthar Prescribing Infrmatin. Hazelwd, MO: Mallinckrdt ARD, Inc.; January Available at Accessed Nvember 13, G CY, Mackay MT, Weiss SK, et al. Evidenced-based guideline update: Medical treatment f infantile spasms: Reprt f the guideline develpment subcmmittee f the American Academy f Neurlgy and the Practice Cmmittee f the Child Neurlgy Sciety. Neurlgy. June 12, 2012; 78(24): Reaffirmed July 18, Pellck JM, Hrachvy R, Shinnar S, et al. Infantile spasms: A U.S. cnsensus reprt. Epilepsia. Octber 2010; 51(10): Berkvich R, Agius M. Mechanisms f actin f ACTH in the management f relapsing frms f multiple sclersis. Ther Adv Neurl Disrd. March 2014; 7(2): Filippini G, Brusaferri F, Sibley WA, et al. Crticsterids r ACTH fr acute exacerbatins in multiple sclersis. Cchrane Database Syst Rev. 2000; (4): CD Page 3 f 5
4 6. Berkvich R, Bakshi R, Amezcua L, et al. Adrencrtictrpic hrmne versus methylprednislne added t interfern B in patients with multiple sclersis experiencing breakthrugh disease: A randmized, rater-blinded trial. Ther Adv Neurl Disrd. January 2017; 10(1): Beck L, Bmback AS, Chi M, et al. KDOQI cmmentary n the 2012 KDIGO clinical practice guidelines fr glmerulnephritis. Am J Kidney Dis. 2013: 62(3): Lieberman KV and Pavlva-Wlf A. Adrencrtictrpic hrmne therapy fr the treatment f idipathic nephrtic syndrme in children and yung adults: A systematic review f early clinical studies with cntemprary relevance. J Nephrl. 2017; 30: Hladunewich MA, Cattran D, Beck LH, et al. A pilt study t determine the dse and effectiveness f adrencrtictrphic hrmne (H.P. Acthar Gel) in nephrtic syndrme due t idipathic membranus nephrpathy. Nephrl Dial Transplant. 2014; 29: Hgan J, Bmback AS, Mehta K, et al. Treatment f idipathic FSGS with adrencrtictrpic hrmne gel. Clin J Am Sc Nephrl. December 6, 2013; 8(12): Chen Y, Schieppati A, Cai G, et al. Immunsuppressin fr membranus nephrpathy: A systematic review and meta-analysis f 36 clinical trials. Clin J Am Sc Nephrl. May 7, 2013; 8(5): Madan A, Mijvic-Das S, Stankvic A, et al. Acthar gel in the treatment f nephrtic syndrme: A multicenter retrspective case series. BMC Nephrl. March 31, 2016; 17: Thmpsn AJ, Kennard C, Swash M, Summers B, Yuill GM, Shepherd DI, et al. Relative efficacy f intravenus methylprednislne and ACTH in the treatment f acute relapse in MS. Neurlgy 1989; 39(7): Clinical Pharmaclgy [database nline]. Tampa, FL: Gld Standard, Inc.; Available at: Reviews, Revisins, and Apprvals Date P&T Apprval Date Plicy split frm USS.CP.PHAR.56 H.P. Acthar and Sabril and cnverted t new template. Remved all requests fr dcumentatin and safety criteria. Remved labeled indicatins and criteria that d nt have clinical studies shwing effectiveness and superirity ver crticsterid therapy. Retained criteria fr infantile spasms and MS. Infantile spasms: mdified apprval duratin t 4 weeks. MS: added age/dsing and mdified apprval duratin t max 3 weeks based n PI; added criteria fr failure r cntraindicatin f ral crticsterids fr MS; added requirement fr adherent use f disease mdifying therapy Cnverted t new template Added Nephrtic syndrme and ther indicatins criteria. - Updated references Q18 annual review: - Remved indicatins nt supprted by well-designed clinical trials as nted in Appendix C; retained indicatin due fr nephrtic syndrme in plicy due t appeal verturn reprt - West syndrme remved EEG requirement t cnfirm diagnsis; added neurlgist prescriber requirement. - MS added requirement fr 7 day curse f crticsterid therapy fr acute exacerbatins; apprval duratin reduced t ne mnth fr initial as this medicatin is nt indicated t used chrnically and fr cntinued apprval fr MS was referred t the initial criteria. - References reviewed and updated. Page 4 f 5
5 Imprtant Reminder This clinical plicy has been develped by apprpriately experienced and licensed health care prfessinals based n a review and cnsideratin f currently available generally accepted standards f medical practice; peer-reviewed medical literature; gvernment agency/prgram apprval status; evidence-based guidelines and psitins f leading natinal health prfessinal rganizatins; views f physicians practicing in relevant clinical areas affected by this clinical plicy; and ther available clinical infrmatin. This Clinical Plicy is nt intended t dictate t prviders hw t practice medicine, nr des it cnstitute a cntract r guarantee regarding payment r results. Prviders are expected t exercise prfessinal medical judgment in prviding the mst apprpriate care, and are slely respnsible fr the medical advice and treatment f members. This plicy is the prperty f Envlve Pharmacy Slutins. Unauthrized cpying, use, and distributin f this Plicy r any infrmatin cntained herein is strictly prhibited. By accessing this plicy, yu agree t be bund by the freging terms and cnditins, in additin t the Site Use Agreement fr Health Plans assciated with Envlve Pharmacy Slutins Envlve Pharmacy Slutins. All rights reserved. All materials are exclusively wned by Envlve Pharmacy Slutins and are prtected by United States cpyright law and internatinal cpyright law. N part f this publicatin may be reprduced, cpied, mdified, distributed, displayed, stred in a retrieval system, transmitted in any frm r by any means, r therwise published withut the prir written permissin f Envlve Pharmacy Slutins. Yu may nt alter r remve any trademark, cpyright r ther ntice cntained herein. Page 5 f 5
Clinical Policy: Repository Corticotropin Injection (H.P. Acthar Gel) Reference Number: CA.PHAR.168
Clinical Policy: (H.P. Acthar Gel) Reference Number: CA.PHAR.168 Effective Date: 05/17 Last Review Date: 07/18 See Important Reminder at the end of this policy for important regulatory and legal information.
More informationClinical Policy: Vedolizumab (Entyvio) Reference Number: ERX.SPA.163 Effective Date:
Clinical Plicy: Vedlizumab (Entyvi) Reference Number: ERX.SPA.163 Effective Date: 10.01.16 Last Review Date: 11.18 Revisin Lg See Imprtant Reminder at the end f this plicy fr imprtant regulatry and legal
More informationClinical Policy: Deutetrabenazine (Austedo) Reference Number: ERX.SPA.150 Effective Date:
Clinical Plicy: (Austed) Reference Number: ERX.SPA.150 Effective Date: 09.01.17 Last Review Date: 05.18 Revisin Lg See Imprtant Reminder at the end f this plicy fr imprtant regulatry and legal infrmatin.
More informationClinical Policy: Corticotropin (H.P. Acthar) Reference Number: ERX.SPA.72 Effective Date:
Clinical Policy: (H.P. Acthar) Reference Number: ERX.SPA.72 Effective Date: 10.01.16 Last Review Date: 11.18 Revision Log See Important Reminder at the end of this policy for important regulatory and legal
More informationDrug Therapy Guidelines
Drug Therapy Guidelines Orencia (abatacept) Applicable Medical Benefit x Effective: 2/21/18 Pharmacy- Frmulary 1 x Next Review: 12/18 Pharmacy- Frmulary 2 x Date f Origin: 11/28/06 Pharmacy- Frmulary 3/Exclusive
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (H.P. Acthar Gel) Reference Number: CP.PHAR.168 Effective Date: 03.01.16 Last Review Date: 11.18 Line of Business: Commercial, Medicaid See Important Reminder at the end of this policy
More informationFolotyn (pralatrexate)
Fltyn (pralatrexate) Line(s) f Business: HMO; PPO; QUEST Integratin Akamai Advantage Original Effective Date: 10/01/2015 Current Effective Date: 01/01/2018TBD03/01/2017 POLICY A. INDICATIONS The indicatins
More informationRituxan (rituximab) Effective Date: 10/01/2015. Line(s) of Business: HMO; PPO; QUEST Integration Akamai Advantage
Rituxan (rituximab) Line(s) f Business: HMO; PPO; QUEST Integratin Akamai Advantage Effective Date: 10/01/2015 POLICY A. INDICATIONS The indicatins belw including FDA-apprved indicatins and cmpendial uses
More information2017 Optum, Inc. All rights reserved BH1124_112017
1) What are the benefits t clients f encuraging the use f MAT? Withut MAT, 90% f individuals with Opiid Use Disrder (OUD) will relapse within ne year. With MAT, the relapse rate fr thse with OUD decreases
More informationDrug Therapy Guidelines
Applicable* Medical Benefit x Effective: 2/15/19 Pharmacy- Frmulary 1 Next Review: 12/19 Pharmacy- Frmulary 2 Date f Origin: 4/1/05 Pharmacy- Frmulary 3/Exclusive Review Dates: 4/1/05, 2/1/06, 10/15/06,
More informationWidening of funding restrictions for rituximab and eltrombopag
20 February 2014 Widening f funding restrictins fr rituximab and eltrmbpag PHARMAC is pleased t annunce the apprval f prpsals t widen the restrictin n rituximab use in DHB hspitals and expand the funding
More informationCLINICAL MEDICAL POLICY
Plicy Name: Plicy Number: Respnsible Department(s): CLINICAL MEDICAL POLICY Supervised Exercise Therapy fr Peripheral Artery Disease (PAD) MP-077-MD-DE Medical Management Prvider Ntice Date: 01/15/2019
More informationDrug Therapy Guidelines
Drug Therapy Guidelines Applicable* Hereditary Angiedema (HAE) Agents: Berinert (C1 esterase inhibitr [human]), Cinryze (C1 esterase inhibitr [human]), Haegarda (C1 esterase inhibitr [human]) Kalbitr (ecallantide),
More informationOriginal Policy Date 12:2013
MP 5.01.18 Xlair (Omalizumab) Medical Plicy Sectin Prescriptin Drugs Issu12:2013e 4:2006 Original Plicy Date 12:2013 Last Review Status/Date Lcal plicy/12:2013 Return t Medical Plicy Index Disclaimer Our
More informationo Prostanoids/prostacyclin therapies (oral and inhaled) o Inhaled agents: Ventavis, Tyvaso Page 1 of 5 Revised 02/17/17
Request fr Prir Authrizatin Pulmnary Arterial Hypertensin (PAH) Agents (Oral and Inhaled) Website Frm www.highmarkhealthptins.cm Submit request via: Fax - 1-855-476-4158 All requests fr Pulmnary Arterial
More informationIntravenous Vancomycin Use in Adults Intermittent (Pulsed) Infusion
Backgrund This plicy cvers the use f intravenus vancmycin prescribed as an intermittent (pulsed) infusin. This can be used fr treatment r prphylaxis. Evidence supprting this guidance is detailed belw.
More informationSUMMACARE COMMERCIAL MEDICATION REQUEST GUIDELINES. ANTI-OBESITY AGENTS Generic Brand HICL GCN Exception/Other QSYMIA 32515, 32744, 32746, 32745
Generic Brand HICL GCN Exceptin/Other NALTREXONE CONTRAVE ER 41389 /BUPROPION LORCASERIN BELVIQ 34733 PHENTERMINE PHENTERMINE 20691 20692 20693 20713 PHENTERMINE LOMAIRA 20715 PHENTERMINE/TO PIRAMATE GUIDELINES
More informationContinuous Quality Improvement: Treatment Record Reviews. Third Thursday Provider Call (August 20, 2015) Wendy Bowlin, QM Administrator
Cntinuus Quality Imprvement: Treatment Recrd Reviews Third Thursday Prvider Call (August 20, 2015) Wendy Bwlin, QM Administratr Gals f the Presentatin Review the findings f Treatment Recrd Review results
More informationIntravenous Vancomycin Use in Adults Intermittent (Pulsed) Infusion
Intravenus Vancmycin Use in Adults Intermittent (Pulsed) Infusin Backgrund This plicy cvers the use f intravenus vancmycin prescribed as an intermittent (pulsed) infusin. This can be used fr treatment
More informationRelated Policies None
Medical Plicy MP 3.01.501 Guidelines fr Cverage f Mental and Behaviral Health Services Last Review: 8/30/2017 Effective Date: 8/30/2017 Sectin: Mental Health End Date: 08/19/2018 Related Plicies Nne DISCLAIMER
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study Synpsis fr Public Disclsure This clinical study synpsis is prvided in line with Behringer Ingelheim s Plicy n Transparency and Publicatin f Clinical Study Data. The synpsis which is
More informationContinuous Positive Airway Pressure (CPAP) and Respiratory Assist Devices (RADs) including Bi-Level PAP
Cntinuus Psitive Airway Pressure (CPAP) and Respiratry Assist Devices (RADs), Including Bi-Level PAP Benefit Criteria t Change fr Texas Medicaid Effective March 1, 2017 Overview f Benefit Changes Benefit
More informationDrug Therapy Guidelines
Applicable Medical Benefit x Effective: 5/1/18 Pharmacy- Frmulary 1 x Next Review: 3/18 Pharmacy- Frmulary 2 x Date f Origin: 4/99 Gnadtrpin-Releasing Hrmne Agnists- Eligard, Luprn, Luprn-Dept, Luprn Dept-Ped,
More informationOpioid Analgesics PA Request Provider Checklist
WVP Health Authrity Updated 05-12-2015 Opiid Analgesics PA Request Prvider Checklist *** If pssible, please include the fllwing infrmatin with PA requests fr piid analgesics. Including the requested infrmatin
More informationP02-03 CALA Program Description Proficiency Testing Policy for Accreditation Revision 1.9 July 26, 2017
P02-03 CALA Prgram Descriptin Prficiency Testing Plicy fr Accreditatin Revisin 1.9 July 26, 2017 P02-03 CALA Prgram Descriptin Prficiency Testing Plicy fr Accreditatin TABLE OF CONTENTS TABLE OF CONTENTS...
More informationLEVEL OF CARE GUIDELINES: INTENSIVE BEHAVIORAL THERAPY/APPLIED BEHAVIOR ANALYSIS FOR AUTISM SPECTRUM DISORDER HAWAII MEDICAID QUEST
OPTUM LEVEL OF CARE GUIDELINES: INTENSIVE BEHAVIORAL THERAPY / APPLIED BEHAVIOR ANALYSIS FOR AUTISM SPECTRUM DISORDER HAWAII MEDICAID QUEST LEVEL OF CARE GUIDELINES: INTENSIVE BEHAVIORAL THERAPY/APPLIED
More informationMylotarg (gemtuzumab ozogamicin) (Intravenous)
Myltarg (gemtuzumab zgamicin) (Intravenus) Last Review Date: 09/19/2017 Date f Origin: 09/19/2017 Dates Reviewed: 09/2017 Dcument Number: IC-0320 I. Length f Authrizatin Newly-Diagnsed AML De nv disease
More informationClinical Policy: Somatropin (Recombinant Human Growth Hormone) Reference Number: ERX.SPA.14 Effective Date:
Clinical Plicy: Smatrpin (Recmbinant Human Grwth Hrmne) Reference Number: ERX.SPA.14 Effective Date: 07.01.16 Last Review Date: 05.18 Revisin Lg See Imprtant Reminder at the end f this plicy fr imprtant
More informationBenefits for Anesthesia Services for the CSHCN Services Program to Change Effective for dates of service on or after July 1, 2008, benefit criteria
Benefits fr Anesthesia Services fr the CSHCN Services Prgram t Change Effective fr dates f service n r after July 1, 2008, benefit criteria fr anesthesia will change fr the Children with Special Health
More information2016 CWA Political Action Fund Administrative Procedures Checklist
2016 CWA Plitical Actin Fund Administrative Prcedures Checklist 1. Dates f Prgram The 2016 CWA Plitical Actin Fund (federal plitical actin cmmittee- CWA-COPE PCC) Prgram will be cnducted n a calendar year
More informationBariatric Surgery FAQs for Employees in the GRMC Group Health Plan
Bariatric Surgery FAQs fr Emplyees in the GRMC Grup Health Plan Gergia Regents Medical Center and Gergia Regents Medical Assciates emplyees and eligible dependents wh are in the GRMC Grup Health Plan (Select
More informationHealth Screening Record: Entry Level Due: August 1st MWF 150 Entry Year
Health Screening Recrd: Entry Level MIDWIFERY EDUCATION PROGRAM HEALTH SCREENING REQUIREMENTS (Rev. June 2017) 1. Hepatitis B: Primary vaccinatin series (3 vaccines 0, 1 and 6 mnths apart), plus serlgic
More informationCancer Association of South Africa (CANSA)
Cancer Assciatin f Suth Africa (CANSA) Fact Sheet and Psitin Statement n Cannabis in Suth Africa Intrductin Cannabis is a drug that cmes frm Indian hemp plants such as Cannabis sativa and Cannabis indica.
More informationHIP REPLACEMENT SURGERY (ARTHROPLASTY)
Prtcl: ORT015 Effective Date: June 1, 2017 HIP REPLACEMENT SURGERY (ARTHROPLASTY) Table f Cntents Page COMMERCIAL & MEDICAID COVERAGE RATIONALE... 1 MEDICARE COVERAGE RATIONALE... 3 U.S.FOOD AND DRUG ADMINISTRATION
More informationRequest for Prior Authorization for Click here to enter text. Website Form Submit request via: Fax
Request fr Prir Authrizatin fr Click here t enter text. Website Frm www.highmarkhealthptins.cm Submit request via: Fax - 1-855-476-4158 Updated: 05/2018 DMMA Apprved: 05/2018 All requests fr Intravenus
More informationAnnex III. Amendments to relevant sections of the Product Information
Changes t the Prduct infrmatin as apprved by the CHMP n 13 Octber 2016, pending endrsement by the Eurpean Cmmissin Annex III Amendments t relevant sectins f the Prduct Infrmatin Nte: These amendments t
More informationCardiac Rehabilitation Services
Dcumentatin Guidance N. DG1011 Cardiac Rehabilitatin Services Revisin Letter A 1.0 Purpse The Centers fr Medicare and Medicaid Services (CMS) has detailed specific dcumentatin requirements fr Cardiac Rehabilitatin
More informationCommissioning Policy: South Warwickshire CCG (SWCCG)
Cmmissining Plicy: Suth Warwickshire CCG (SWCCG) Treatment Indicatin Criteria FreeStyle Libre Flash Cntinuus Glucse Mnitring System Type I Diabetes Prir apprval must be requested frm the Individual Funding
More informationKadcyla (ado-trastuzumab emtansine) Document Number: IC-0092
Kadcyla (ad-trastuzumab emtansine) Dcument Number: IC-0092 Last Review Date: 2/6/2018 Date f Origin: 05/16/2013 Dates Reviewed: 7/2013, 11/2013, 12/2013, 3/2014, 6/2014, 9/2014, 12/2014, 5/2015, 8/2015,
More informationFee Schedule - Home Health Care- 2015
Fee Schedule - Hme Health Care- 2015 01/01/2015 1600 E Century Ave Ste 1 PO Bx 5585 Bismarck ND 58506-5585 www.wrkfrcesafety.cm Cpyright Ntice The five character cdes included in the Nrth Dakta Fee Schedule
More informationDrug Therapy Guidelines
Drug Therapy Guidelines Applicable Medical Benefit x Effective: 5/1/18 Pharmacy- Frmulary 1 x Next Review: 6/18 Pharmacy- Frmulary 2 x Date f Origin: 11/07 Immune Glbulins Intravenus: Carimune NF, Flebgamma,
More information2017 CMS Web Interface
CMS Web Interface PREV-5 (NQF 2372): Breast Cancer Screening Measure Steward: NCQA Web Interface V1.0 Page 1 f 18 11/15/2016 Cntents INTRODUCTION... 3 WEB INTERFACE SAMPLING INFORMATION... 4 BENEFICIARY
More informationErythropoiesis Stimulating Agents (ESAs): Aranesp (darbepoetin alfa) Related Medical Guideline Off-Label Use of FDA-Approved Drugs and Biologicals
(Subcutaneus/Intravenus) Last Review Date: January 1, 2019 Number: MG.MM.PH.80 *NON-DIALYSIS* Medical Guideline Disclaimer C All rights reserved. The treating physician r primary care prvider must submit
More informationQ 5: Is relaxation training better (more effective than/as safe as) than treatment as usual in adults with depressive episode/disorder?
updated 2012 Relaxatin training Q 5: Is relaxatin training better (mre effective than/as safe as) than treatment as usual in adults with depressive episde/disrder? Backgrund The number f general health
More informationAssessment Field Activity Collaborative Assessment, Planning, and Support: Safety and Risk in Teams
Assessment Field Activity Cllabrative Assessment, Planning, and Supprt: Safety and Risk in Teams OBSERVATION Identify a case fr which a team meeting t discuss safety and/r safety planning is needed r scheduled.
More informationEXECUTIVE SUMMARY INNOVATION IS THE KEY TO CHANGING THE PARADIGM FOR THE TREATMENT OF PAIN AND ADDICTION TO CREATE AN AMERICA FREE OF OPIOID ADDICTION
EXECUTIVE SUMMARY INNOVATION IS THE KEY TO CHANGING THE PARADIGM FOR THE TREATMENT OF PAIN AND ADDICTION TO CREATE AN AMERICA FREE OF OPIOID ADDICTION The Bitechnlgy Innvatin Organizatin (BIO) and ur member
More informationTO: Mayor & Council DATE: March 8, The Planning & Development Department and the Legal Services Division recommend that Council:
CORPORATE REPORT NO: R049 COUNCIL DATE: March 12, 2018 REGULAR COUNCIL TO: Mayr & Cuncil DATE: March 8, 2018 FROM: SUBJECT: General Manager, Planning & Develpment City Slicitr, Legal Services Cannabis
More informationOTHER AND UNSPECIFIED DISORDERS
OPTUM COVERAGE DETERMINATION GUIDELINE OTHER AND UNSPECIFIED DISORDERS Guideline Number: BH727OUD_102017 Effective Date: Octber, 2017 Table f Cntents Page INSTRUCTIONS FOR USE... 1 BENEFIT CONSIDERATIONS...
More informationCONSENT FOR KYBELLA INJECTABLE FAT REDUCTION
CONSENT FOR KYBELLA INJECTABLE FAT REDUCTION INSTRUCTIONS This is an infrmed cnsent dcument which has been prepared t help yur Dctr infrm yu cncerning fat reductin with an injectable medicatin, its risks,
More informationNew Exception Status Benefits
FEBRUARY 2019 Nva Sctia Frmulary Updates New Exceptin Status Benefits Prcysbi (cysteamine bitartrate) Nucala (meplizumab) Ocaliva (betichlic acid) Ravicti (glycerl phenylbutyrate) Taltz (ixekizumab) Criteria
More informationPharmacy Prior Authorization Growth Hormone- Clinical Guidelines. Serostim Zorbtive somatropin
Pharmacy Prir Authrizatin Grwth Hrmne- Clinical Guidelines Gentrpin Humatrpe Nrditrpin Nutrpin Omnitrpe Saizen Serstim Zmactn Zrbtive smatrpin General Criteria fr Apprval: Omnitrpe vial frmulatin is the
More informationGuideline Number: NIA_CG_301 Last Revised Date: October 2014 Responsible Department: Implementation Date: October 2014 Clinical Operations
Natinal Imaging Assciates, Inc. Clinical guidelines PARAVERTEBRAL FACET JOINT INJECTIONS OR BLOCKS CPT Cdes: Cervical Thracic Regin: 64490 (+ 64491, +64492), 0213T (+0214T, +0215T) Lumbar Sacral Regin:
More informationGeneric Immunosuppressants in the Specialist Area of Transplantation Consensus on Implications and Practical Recommendations
Dear Clleague Generic Immunsuppressants in the Specialist Area f Transplantatin Cnsensus n Implicatins and Practical Recmmendatins Executive Summary Slid-rgan transplants are the best pssible treatment
More informationGUIDANCE DOCUMENT FOR ENROLLING SUBJECTS WHO DO NOT SPEAK ENGLISH
GUIDANCE DOCUMENT FOR ENROLLING SUBJECTS WHO DO NOT SPEAK ENGLISH Aurra Health Care s Research Subject Prtectin Prgram (RSPP) This guidance dcument will utline the prper prcedures fr btaining and dcumenting
More information1.11 INSULIN INFUSION PUMP MANAGEMENT INPATIENT
WOMEN AND NEWBORN HEALTH SERVICE CLINICAL GUIDELINES SECTION A: GUIDELINES RELEVANT TO OBSTETRICS AND GYNAECOLOGY 1 STANDARD PROTOCOLS 1.11 INSULIN INFUSION PUMP MANAGEMENT - INPATIENT Authrised by: OGCCU
More informationSPINRAZA (NUSINERSEN)
SPINRAZA (NUSINERSEN) UnitedHealthcare Oxfrd Clinical Plicy Plicy Number: PHARMACY 295.4 T2 Effective Date: April 1, 2018 Table f Cntents Page INSTRUCTIONS FOR USE... 1 CONDITIONS OF COVERAGE... 1 BENEFIT
More informationA fake medicine that passes itself off as a real, authorised medicine. (1)
Falsified medicines Index 1 Intrductin 2 Types f falsified medicines 3 Eurpean regulatin n falsified medicines 4 Risks f falsified medicines 5 Buying medicine nline safely 6 References 7 Further resurces
More informationCompleting the NPA online Patient Safety Incident Report form: 2016
Cmpleting the NPA nline Patient Safety Incident Reprt frm: 2016 The infrmatin cntained within this dcument is in line with the current Data Prtectin Act (DPA) requirements. This infrmatin may be subject
More informationMEDICATION GUIDE. (Interferon alfa-2b)
MEDICATION GUIDE INTRON A (In-trn-aye) (Interfern alfa-2b) Read this Medicatin Guide befre yu start taking INTRON A, and each time yu get a refill. There may be new infrmatin. This infrmatin des nt take
More informationDiabetes Mellitus Lab Tests (Screening, Diagnosis & Monitoring)
Rule Categry: Medical ` Ref: N: 2013-MN-0012 Versin Cntrl: Versin N. 1.1 Effective Date: December 2013 Revisin Date: December 2014 Diabetes Mellitus Lab Tests (Screening, Diagnsis & Mnitring) Adjudicatin
More informationFamily Medicine Clinical Pharmacy Forum Vol. 3, Issue 5 (September/October 2007)
1 Family Medicine Clinical Pharmacy Frum Vl. 3, Issue 5 (September/Octber 2007) Family Medicine Clinical Pharmacy Frum is a brief bi-mnthly publicatin frm the Family Medicine clinical pharmacists distributed
More informationWound Care Equipment and Supply Benefits to Change for Texas Medicaid July 1, 2018
Wund Care Equipment and Supply Benefits t Change fr Texas Medicaid July 1, 2018 Infrmatin psted May 11, 2018 Nte: Texas Medicaid managed care rganizatins (MCOs) must prvide all medically necessary, Medicaid-cvered
More informationNIA Magellan 1 Spine Care Program Interventional Pain Management Frequently Asked Questions (FAQs) For Medicare Advantage HMO and PPO
NIA Magellan 1 Spine Care Prgram Interventinal Pain Management Frequently Asked Questins (FAQs) Fr Medicare Advantage HMO and PPO Questin GENERAL Why is Flrida Blue implementing a Spine Management prgram
More information2017 CMS Web Interface
CMS Web Interface PREV-6 (NQF 0034): Clrectal Cancer Screening Measure Steward: NCQA Web Interface V1.0 Page 1 f 18 11/15/2016 Cntents INTRODUCTION... 3 WEB INTERFACE SAMPLING INFORMATION... 4 BENEFICIARY
More informationIndications and Limitations of Coverage and/or Medical back to top
Fr services perfrmed n r after 09/15/2009 Original Determinatin Ending Date Revisin Effective Date Revisin Ending Date Indicatins and Limitatins f Cverage and/r Medical Necessity Indicatins Medicare cverage
More informationCatherine Worthingham Fellows of APTA Instructions for Writing a Letter of Support
Catherine Wrthingham Fellws f APTA Instructins fr Writing a Letter f Supprt Fllwing is infrmatin designed t assist persns asked t write a letter f supprt fr a nminee fr the American Physical Therapy Assciatin
More informationH.P. Acthar Gel (repository corticotropin) Prior Authorization Criteria Program Summary
OBJECTIVE The intent of the H.P. Acthar Gel (repository corticotropin) Prior Authorization (PA) Criteria is to appropriately select patients for therapy according to product labeling and/or clinical studies
More informationQP Energy Services LLC Hearing Conservation Program HSE Manual Section 7 Effective Date: 5/30/15 Revision #:
QP Energy Services LLC Hearing Cnservatin Prgram HSE Manual Sectin 7 Effective Date: 5/30/15 Revisin #: Prepared by: James Aregd Date: 5/30/15 Apprved by: James Aregd Date: 5/30/15 Page 1 f 8 Cntents Sectin
More informationITP typically presents with the sudden appearance of a petechial rash, spontaneous bruising and/or bleeding in an otherwise well child.
Acute Immune Thrmbcytpenia Purpura (ITP) Backgrund Primary immune thrmbcytpenia (ITP) is an acquired immune mediated disrder characterised by islated thrmbcytpenia, defined as a peripheral bld platelet
More informationPerjeta (pertuzumab) Document Number: IC I. Length of Authorization. Dosing Limits. Initial Approval Criteria
Perjeta (pertuzumab) Last Review Date: 11/21/2017 Date f Origin: 11/01/2012 Dcument Number: IC-0096 Dates Reviewed: 12/2012, 3/2013, 6/2013, 9/2013, 11/2013, 12/2013, 3/2014, 6/2014, 9/2014, 12/2014, 3/2015,
More informationUNM SRMC SLEEP MEDICINE CLINICAL PRIVILEGES.
Initial privileges (initial appintment) Renewal f privileges (reappintment) Expansin f privileges (mdificatin) INSTRUCTIONS All new applicants must meet the fllwing requirements as apprved by the UNM SRMC
More informationMEDICARE COVERAGE SUMMARY: TRANSCRANIAL MAGNETIC STIMULATION
OPTUM MEDICARE COVERAGE SUMMARY: TRANSCRANIAL MAGNETIC STIMULATION MEDICARE COVERAGE SUMMARY: TRANSCRANIAL MAGNETIC STIMULATION Guideline Number: Effective Date: April, 2018 INSTRUCTIONS FOR USE This guideline
More information2018 CMS Web Interface
CMS Web Interface HTN-2 (NQF 0018): Cntrlling High Bld Pressure Measure Steward: NCQA CMS Web Interface V2.0 Page 1 f 18 11/13/2017 Cntents INTRODUCTION... 3 CMS WEB INTERFACE SAMPLING INFORMATION... 4
More informationPACKAGE LEAFLET: INFORMATION FOR THE USER
(Sanfi-Aventis France), NT001 Suppliers submissin f the SRA apprved text Octber 2016 Name f the medicinal prduct Text bx PACKAGE LEAFLET: INFORMATION FOR THE USER NOTEZINE 100 mg, scred tablets Diethylcarbamazine
More informationUS Public Health Service Clinical Practice Guidelines for PrEP
Webcast 1.3 US Public Health Service Clinical Practice Guidelines fr PrEP P R E S ENTED BY: M A R K T H R U N, M D A S S O C I AT E P R O F E S S O R, U N I V E R S I T Y O F C O L O R A D O, D I V I S
More informationDear Student, IMMUNIZATION RECORD INSTRUCTIONS
Dear Student, Welcme t the University f Chicag! The State f Illinis and University regulatins require students t prvide prf f required immunizatins prir t registratin fr classes. In rder t cmplete this
More informationTick fever is a cattle disease caused by any one of the following blood parasites:
Tick fever Tick fever is a cattle disease caused by any ne f the fllwing bld parasites: Babesia bvis Babesia bigemina Anaplasma marginale These parasites are all transmitted by the cattle tick (Bphilus
More informationBRCA1 and BRCA2 Mutations
BRCA1 and BRCA2 Mutatins ROBERT LEVITT, MD JESSICA BERGER-WEISS, MD ADRIENNE POTTS, MD HARTAJ POWELL, MD, MPH COURTNEY LEVENSON, MD LAUREN BURNS, MSN, RN, WHNP OBGYNCWC.COM v Cancer is a cmplex disease
More informationCDC Influenza Division Key Points MMWR Updates February 20, 2014
CDC Influenza Divisin Key Pints MMWR Updates In this dcument: Summary Key Messages Seasnal Influenza Vaccine Effectiveness: Interim Adjusted Estimates Influenza Surveillance Update: September 29, 2013-February
More informationInstructions and Helpful Information for D-5 Form. Preliminary Approval of Dissertation and Request for Oral Defense (D-5)
Instructins and Helpful Infrmatin fr D-5 Frm Preliminary Apprval f Dissertatin and Request fr Oral Defense (D-5) 1. DEADLINES D-5 must be submitted t the UGS at least 3 WEEKS BEFORE the date f the defense
More informationMethadone Maintenance Treatment for Opioid Dependence
POLICY STATEMENT Methadne Maintenance Treatment fr Opiid Dependence APPROVED BY COUNCIL: May 2010 PUBLICATION DATE: Dialgue, Issue 2, 2010 Disclaimer: As f May 19, 2018 physicians n lnger require an exemptin
More information(Please text me on once you have submitted your request online and the cell number you used)
Dear Thank yu fr yur email, nted. Belw steps n hw t register as a service prvider. Please nte that nce yu have requested t becme a service prvider, yu need t sms/what s up me n 0826392585, in rder t activate
More informationClinical Policy: Rivastigmine (Exelon) Reference Number: CP.PMN.101 Effective Date: Last Review Date: 02.18
Clinical Policy: (Exelon) Reference Number: CP.PMN.101 Effective Date: 03.01.17 Last Review Date: 02.18 Line of Business: Medicaid Revision Log See Important Reminder at the end of this policy for important
More informationCorporate Governance Code for Funds: What Will it Mean?
Crprate Gvernance Cde fr Funds: What Will it Mean? The Irish Funds Industry Assciatin has circulated a draft Vluntary Crprate Gvernance Cde fr the Funds Industry in Ireland. 1. Backgrund On 13 June 2011,
More informationOrencia (abatacept) Document Number: MODA-0091
Orencia (abatacept) Dcument Number: MODA-0091 Last Review Date: 09/19/2017 Date f Origin: 07/02/2010 Dates Reviewed: 07/2010, 09/2010, 12/2010, 02/15/11, 03/2011, 06/2011, 09/2011, 12/2011, 03/2012, 06/2012,
More informationNational Imaging Associates, Inc. (NIA) Frequently Asked Questions (FAQs) For Managed Health Services (MHS)
Questin GENERAL Why did MHS implement a Medical Specialty Slutins Prgram? Natinal Imaging Assciates, Inc. (NIA) Frequently Asked Questins (FAQs) Fr Managed Health Services (MHS) Answer Effective Nvember
More informationYescarta (axicabtagene ciloleucel) (Intravenous)
Yescarta (axicabtagene cilleucel) (Intravenus) Last Review Date: 10/31/2017 Date f Origin: 10/31/2017 Dates Reviewed: 10/2017 Dcument Number: IC-0333 I. Length f Authrizatin Cverage will be prvided fr
More informationSolid Organ Transplant Benefits to Change for Texas Medicaid
Slid Organ Transplant Benefits t Change fr Texas Medicaid Infrmatin psted February 13, 2015 Nte: All new and updated prcedure cdes and their assciated reimbursement rates are prpsed benefits pending a
More informationcerliponase alfa (Brineura )
cerlipnase alfa (Brineura ) Applies t all prducts administered r underwritten by Blue Crss and Blue Shield f Luisiana and its subsidiary, HMO Luisiana, Inc.(cllectively referred t as the Cmpany ), unless
More informationMEDICATION GUIDE. (fingolimod) capsules
MEDICATION GUIDE GILENYA (je-len-yah) (finglimd) capsules Read this Medicatin Guide befre yu start using GILENYA and each time yu get a refill. There may be new infrmatin. This infrmatin des nt take the
More informationMEASURE #10: PLAN OF CARE FOR MIGRAINE OR CERVICOGENIC HEADACHE DEVELOPED OR REVIEWED Headache
MEASURE #10: PLAN OF CARE FOR MIGRAINE OR CERVICOGENIC HEADACHE DEVELOPED OR REVIEWED Headache Measure Descriptin All patients diagnsed with migraine headache r cervicgenic headache wh had a headache management
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Glumetza, Fortamet) Reference Number: CP.HNCA.72 Effective Date: 11.01.15 Last Review Date: 05.18 Line of Business: Commercial - HNCA Revision Log See Important Reminder at the end of
More informationMedical Student Immunization Requirements
Medical Student Immunizatin Requirements The State f Illinis cde, Reference: (110 ILCS 20) Cllege Student Immunizatin Act, requires students t prvide prf f immunity: Measles (Rubela), Mumps, Rubella (German
More informationYear 10 Food Technology. Assessment Task 1: Foods for Special Needs. Name: Teacher:
Year 10 Fd Technlgy Assessment Task 1: Fds fr Special Needs Name: Teacher: Due Date: Term 2, Week 1 Type f Task: Design Task Planning Fd Requirements Cllectin f Assessment: Submit in Class Assessment Plicy:
More informationSECTION O. MEDICATIONS
SECTION O. MEDICATIONS 1. NUMBER OF MEDICA TIONS (Recrd the number f different medicatins used in the last 7 days; enter "0" if nne used) O1. Number f Medicatins (7-day lk back) Intent: Prcess: Cding:
More informationPublic consultation on the NHMRC s draft revised Australian alcohol guidelines for low-risk drinking
Public cnsultatin n the NHMRC s draft revised Australian alchl guidelines fr lw-risk drinking Recmmendatins frm The Cancer Cuncil Australia The Cancer Cuncil Australia is Australia s peak nn-gvernment
More information